I 

109TH CONGRESS 

1ST SESSION H. R. 3144 

To amend the Public Health Service Act to provide for a program at the 

National Institutes of Health to conduct and support research in the 

derivation and use of human pluripotent stem cells by means that do 

not harm human embryos, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

JUNE 30, 2005 

Mr. BARTLETT of Maryland (for himself, Mr. GINGREY, Mr. BLUNT, Ms. 

PRYCE of Ohio, Mr. BEAUPREZ, Mr. GUTKNECHT, Mr. NORWOOD, Mr. 

OSBORNE, Mr. MARSHALL, Mr. CULBERSON, Mr. WELLER, Mr. ROHRABACHER, Mr. PRICE of Georgia, Mr. HEFLEY, Mr. BILIRAKIS, Mr. 

ENGLISH of Pennsylvania, Mr. CANNON, Mr. GILCHREST, and Mr. DEAL

of Georgia) introduced the following bill; which was referred to the Committee on Energy and Commerce 

A BILL 

To amend the Public Health Service Act to provide for 

a program at the National Institutes of Health to conduct and support research in the derivation and use 

of human pluripotent stem cells by means that do not 

harm human embryos, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Respect for Life 

5 Pluripotent Stem Cell Act of 2005’’. 
2 

•HR 3144 IH 

1 SEC. 2. FINDINGS. 

2 The Congress finds as follows: 

3 (1) Stem cells may be derived from various 

4 sources, including adult tissue, umbilical cord blood, 

5 and living human embryos. The use of cells from 

6 embryos has drawn great interest in the scientific 

7 community but also raises very serious ethical con8 cerns for many Americans, because as practiced 

9 today it requires the destruction of human embryos 

10 to obtain their cells. 

11 (2) The President’s Council on Bioethics in its 

12 May 2005 White Paper: ‘‘Alternative Sources of 

13 Pluripotent Stem Cells,’’ describes several potential 

14 methods to derive stem cells like those now derived 

15 through the destruction of embryos, but which would 

16 not involve doing harm to embryos. Some methods 

17 propose to involve embryos in ways that do not harm 

18 them, while others propose to reprogram adult cells 

19 to produce cells with the capabilities of embryonic 

20 stem cells without producing or involving embryos at 

21 all. 

22 (3) Such proposals should be thoroughly tested 

23 in animal models before being applied to humans, to 

24 establish that they do not involve creating or harm25 ing human embryos. 
3 

•HR 3144 IH 

1 (4) Several scientific reports also suggest that 

2 some subclasses of adult stem cells (derived from 

3 postnatal tissues, umbilical cord blood and placenta) 

4 show a flexibility comparable to that of stem cells 

5 now derived through the destruction of embryos. 

6 (5) American scientists should be encouraged to 

7 pursue all ethical avenues of stem cell research and 

8 to explore morally uncontroversial alternatives to re9 search requiring the destruction of human embryos. 

10 SEC. 3. DERIVATION OF STEM CELLS WITHOUT HARMING 

11 EMBRYOS; RESEARCH THROUGH NATIONAL 

12 INSTITUTES OF HEALTH. 

13 Part B of title IV of the Public Health Service Act 

14 (42 U.S.C. 284) is amended by adding at the end the fol15 lowing: 

16 ‘‘SEC. 409J. BASIC AND APPLIED RESEARCH ON DERIVA17 TION AND USE OF PLURIPOTENT STEM 

18 CELLS WITHOUT HARMING EMBRYOS. 

19 ‘‘(a) DEFINITIONS.—In this section, the following 

20 definitions apply: 

21 ‘‘(1) HUMAN EMBRYO.—The term ‘human em22 bryo’ includes any organism, not protected as a 

23 human subject under 45 CFR 46 as of the date of 

24 the enactment of the Respect for Life Pluripotent 

25 Stem Cell Act of 2005, that is derived by fertiliza-
4 

•HR 3144 IH 

1 tion, parthenogenesis, cloning, or any other means 

2 from one or more human gametes or human diploid 

3 cells. 

4 ‘‘(2) PLURIPOTENT STEM CELL.—The term 

5 ‘pluripotent stem cell’ means a cell that can in prin6 ciple be differentiated to produce all or almost all 

7 the cell types of the human body, and therefore has 

8 the same functional capacity as an embryonic stem 

9 cell, regardless of whether it has the same origin. 

10 ‘‘(b) IN GENERAL.—With respect to producing stem 

11 cell lines for important biomedical research, the Director 

12 of NIH shall, through the appropriate national research 

13 institutes, provide for the conduct and support of basic 

14 and applied research in isolating, deriving and using 

15 pluripotent stem cells without creating or harming human 

16 embryos. Such research may include— 

17 ‘‘(1) research in animals to develop and test 

18 techniques for deriving cells from embryos without 

19 doing harm to those embryos; 

20 ‘‘(2) research to develop and test techniques for 

21 producing human pluripotent stem cells without cre22 ating or making use of embryos; and 

23 ‘‘(3) research to isolate, develop and test 

24 pluripotent stem cells from postnatal tissues, umbil25 ical cord blood, and placenta. 
5 

•HR 3144 IH 

1 ‘‘(c) PROHIBITIONS REGARDING HARM TO HUMAN

2 EMBRYOS.—Research under subsection (b) may not in3 clude any research that— 

4 ‘‘(1) involves the use of human embryos; or 

5 ‘‘(2) involves the use of stem cells not otherwise 

6 eligible for funding by the National Institutes of 

7 Health; or 

8 ‘‘(3) involves the use of any stem cell to create 

9 or to attempt to create a human embryo, or 

10 ‘‘(4) poses a significant risk of creating a 

11 human embryo by any means. 

12 ‘‘(d) AUTHORIZATION OF APPROPRIATIONS.—For the 

13 purpose of carrying out this section, there are authorized 

14 to be appropriated $15,000,000 in fiscal year 2006, and 

15 such sums as may be necessary for each of the fiscal years 

16 2007 through 2010. Such authorization is in addition to 

17 other authorizations of appropriations that are available 

18 for such purpose.’’. 

Æ